Reuters logo
BRIEF-Actinogen Medical seeks trading halt
December 29, 2016 / 10:26 PM / a year ago

BRIEF-Actinogen Medical seeks trading halt

Dec 30 (Reuters) - Actinogen Medical Ltd

* requests that its securities be placed into an immediate trading halt pending an announcement regarding actinogen medical’s application to FDA

* application to fda to initiate its Xanadu phase ii clinical trial in us of xanamem in treatment of Alzheimer’s disease. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below